Biochemical premotor biomarkers for Parkinson's disease

A biomarker is a biological characteristic that is objectively measured and evaluated as an indicator of normal biological or pathologic processes or of pharmacologic responses to a therapeutic intervention. We reviewed the current status of target protein biomarkers (eg, total/oligomeric α‐synuclein and DJ‐1) in cerebrospinal fluid, as well as on unbiased processes that can be used to discover novel biomarkers. We have also provide ddetails about strategies toward potential populations/models and technologies, including the need for standardized sampling techniques, to pursue the identification of new biochemical markers in the premotor stage of Parkinson's disease in the future. © 2012 Movement Disorder Society

[1]  W. F. Abdo,et al.  CSF α-synuclein does not differentiate between parkinsonian disorders , 2012, Neurobiology of Aging.

[2]  T. Wichmann,et al.  Metabotropic glutamate receptor 5 antagonist protects dopaminergic and noradrenergic neurons from degeneration in MPTP-treated monkeys. , 2011, Brain : a journal of neurology.

[3]  D. Goodlett,et al.  Salivary α-synuclein and DJ-1: potential biomarkers for Parkinson's disease. , 2011, Brain : a journal of neurology.

[4]  Yu Wang,et al.  Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression , 2011, Annals of neurology.

[5]  C. Tanner,et al.  Exploring the electrocardiogram as a potential tool to screen for premotor Parkinson's disease , 2010, Movement disorders : official journal of the Movement Disorder Society.

[6]  T. Tokuda,et al.  Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease , 2010, Neurology.

[7]  Xiqun Chen,et al.  Urate: a novel biomarker of Parkinson's disease risk, diagnosis and prognosis. , 2010, Biomarkers in medicine.

[8]  B. Mollenhauer,et al.  Quantification of α-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies. , 2010, Biomarkers in medicine.

[9]  Sheng Pan,et al.  Using ‘omics’ to define pathogenesis and biomarkers of Parkinson’s disease , 2010, Expert review of neurotherapeutics.

[10]  K. Blennow,et al.  Inter-laboratory variation in cerebrospinal fluid biomarkers for Alzheimer's disease: united we stand, divided we fall , 2010, Clinical chemistry and laboratory medicine.

[11]  S. Limborska,et al.  Expression analysis of suppression of tumorigenicity 13 gene in patients with Parkinson's disease , 2010, Neuroscience Letters.

[12]  H. Braak,et al.  Lewy pathology in the submandibular gland of individuals with incidental Lewy body disease and sporadic Parkinson’s disease , 2010, Acta Neuropathologica.

[13]  Aneeka M Hancock,et al.  DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. , 2010, Brain : a journal of neurology.

[14]  C. Tanner,et al.  Urate as a predictor of the rate of clinical decline in Parkinson disease. , 2009, Archives of neurology.

[15]  M. Beal,et al.  Metabolomic Profiling in LRRK2-Related Parkinson's Disease , 2009, PloS one.

[16]  Brian Spencer,et al.  Inclusion formation and neuronal cell death through neuron-to-neuron transmission of α-synuclein , 2009, Proceedings of the National Academy of Sciences.

[17]  I. Schlesinger,et al.  Uric acid in Parkinson's disease , 2008, Movement disorders : official journal of the Movement Disorder Society.

[18]  K. Ray Chaudhuri,et al.  Early Parkinson’s disease and non-motor issues , 2008, Journal of Neurology.

[19]  A. Eklund,et al.  GATA transcription factors directly regulate the Parkinson's disease-linked gene α-synuclein , 2008, Proceedings of the National Academy of Sciences.

[20]  A. Lang,et al.  Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. , 2008, Archives of neurology.

[21]  Jing Zhang,et al.  CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. , 2008, American journal of clinical pathology.

[22]  Yan Wang,et al.  Mortalin: A Protein Associated With Progression of Parkinson Disease? , 2008, Journal of neuropathology and experimental neurology.

[23]  W. Matson,et al.  Metabolomic profiling to develop blood biomarkers for Parkinson's disease. , 2008, Brain : a journal of neurology.

[24]  Jean X. Gao,et al.  Application of targeted quantitative proteomics analysis in human cerebrospinal fluid using a liquid chromatography matrix-assisted laser desorption/ionization time-of-flight tandem mass spectrometer (LC MALDI TOF/TOF) platform. , 2008, Journal of proteome research.

[25]  M. Weisskopf,et al.  Plasma urate and risk of Parkinson's disease. , 2007, American journal of epidemiology.

[26]  Jing Zhang.  Proteomics of human cerebrospinal fluid – the good, the bad, and the ugly , 2007, Proteomics. Clinical applications.

[27]  Biaoyang Lin,et al.  A combined dataset of human cerebrospinal fluid proteins identified by multi‐dimensional chromatography and tandem mass spectrometry , 2007, Proteomics.

[28]  J. Growdon,et al.  Molecular markers of early Parkinson's disease based on gene expression in blood , 2007, Proceedings of the National Academy of Sciences.

[29]  T. Tokuda,et al.  Decreased α-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson’s disease. , 2006 .

[30]  R. Barbour,et al.  Phosphorylation of Ser-129 Is the Dominant Pathological Modification of α-Synuclein in Familial and Sporadic Lewy Body Disease* , 2006, Journal of Biological Chemistry.

[31]  I. Ferrer,et al.  Low alpha-synuclein 126 mRNA levels in dementia with Lewy bodies and Alzheimer disease , 2006, Neuroreport.

[32]  E. Masliah,et al.  Increased level of DJ-1 in the cerebrospinal fluids of sporadic Parkinson's disease. , 2006, Biochemical and biophysical research communications.

[33]  Yan Wang,et al.  Proteomic Identification of a Stress Protein, Mortalin/mthsp70/GRP75 , 2006, Molecular & Cellular Proteomics.

[34]  M. Cameron Sullards,et al.  Oxidative Damage of DJ-1 Is Linked to Sporadic Parkinson and Alzheimer Diseases* , 2006, Journal of Biological Chemistry.

[35]  Leigh Anderson,et al.  Quantitative Mass Spectrometric Multiple Reaction Monitoring Assays for Major Plasma Proteins* , 2006, Molecular & Cellular Proteomics.

[36]  David R Goodlett,et al.  Proteomic biomarker discovery in cerebrospinal fluid for neurodegenerative diseases. , 2006, Journal of Alzheimer's disease : JAD.

[37]  D. Allsop,et al.  Detection of oligomeric forms of α‐synuclein protein in human plasma as a potential biomarker for Parkinson's disease , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[38]  B. Hyman,et al.  Alpha-Synuclein and Chaperones in Dementia With Lewy Bodies , 2005, Journal of neuropathology and experimental neurology.

[39]  J. Kaye,et al.  Safety and Acceptability of the Research Lumbar Puncture , 2005, Alzheimer disease and associated disorders.

[40]  M. Sjögren,et al.  The Use of Proteomics in Biomarker Discovery in Neurodegenerative Diseases , 2005, Disease markers.

[41]  Anders Wallin,et al.  Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. , 2005, Clinical chemistry.

[42]  J. Grimm,et al.  Molecular basis for catecholaminergic neuron diversity. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[43]  P. Lewczuk,et al.  Cerebrospinal fluid amyloid β peptide patterns in Alzheimer's disease patients and nondemented controls depend on sample pretreatment: Indication of carrier‐mediated epitope masking of amyloid β peptides , 2004, Electrophoresis.

[44]  Jochen Klucken,et al.  Hsp70 Reduces α-Synuclein Aggregation and Toxicity* , 2004, Journal of Biological Chemistry.

[45]  W. Oertel,et al.  Gene expression profiles derived from single cells in human postmortem brain. , 2004, Brain research. Brain research protocols.

[46]  Vincenzo Bonifati,et al.  Linking DJ-1 to neurodegeneration offers novel insights for understanding the pathogenesis of Parkinson’s disease , 2004, Journal of Molecular Medicine.

[47]  M. Cookson,et al.  α‐Synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[48]  E. Petricoin,et al.  Use of proteomic patterns in serum to identify ovarian cancer , 2002, The Lancet.

[49]  H. Reiber,et al.  Dynamics of brain-derived proteins in cerebrospinal fluid. , 2001, Clinica chimica acta; international journal of clinical chemistry.

[50]  K. Blennow,et al.  Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. , 2001, Archives of neurology.

[51]  T. Dawson.  New Animal Models for Parkinson's Disease , 2000, Cell.

[52]  J. Jankovic,et al.  Effects of cerebrospinal fluid from patients with Parkinson disease on dopaminergic cells. , 1999, Archives of neurology.

[53]  P. Blumbergs,et al.  Multiple-system atrophy: a new α-synuclein disease? , 1998, The Lancet.

[54]  H. Reiber.  Flow rate of cerebrospinal fluid (CSF) — A concept common to normal blood-CSF barrier function and to dysfunction in neurological diseases , 1994, Journal of the Neurological Sciences.

[55]  E. Cochran,et al.  Cerebrospinal Fluid from Patients with Parkinson's Disease Alters the Survival of Dopamine Neurons in Mesencephalic Culture , 1994, Experimental Neurology.

[56]  J. Hughes,et al.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. , 1992, Journal of neurology, neurosurgery, and psychiatry.

[57]  C. Merril,et al.  Cerebrospinal fluid protein analysis in diseases of the nervous system. , 1988, Journal of chromatography.

[58]  B. Ames,et al.  Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[59]  R. Gross.  Detection of elevated levels of -synuclein oligomers in CSF from patients with Parkinson disease , 2010 .

[60]  T. Tokuda,et al.  Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. , 2006, Biochemical and biophysical research communications.

[61]  Yan Liu,et al.  Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. , 2006, Journal of Alzheimer's disease : JAD.

[62]  B. Hyman,et al.  Hsp70 Reduces alpha-Synuclein Aggregation and Toxicity. , 2004, The Journal of biological chemistry.

[63]  J. Szmydynger-Chodobska,et al.  Choroid plexus: Target for polypeptides and site of their synthesis , 2001, Microscopy research and technique.

[64]  P. Blumbergs,et al.  Multiple-system atrophy: a new alpha-synuclein disease? , 1998, Lancet.

[65]  M G Spillantini,et al.  Alpha-synuclein in Lewy bodies. , 1997, Nature.